Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 12/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25709714 | 1.00 | BTN3A1 (0.53) | BTN3A1KMT2AMEN1NPSR1MAPK1 | |
| SCHEMBL16576300 | 1.00 | BTN3A1 (0.53) | BTN3A1KMT2AMEN1NPSR1MAPK1 | |
| SCHEMBL16015972 | 0.95 | BTN3A1 (0.56) | BTN3A1KMT2AMEN1NPSR1MAPK1 | |
| SCHEMBL16153685 | 0.90 | BTN3A1 (0.54) | BTN3A1KMT2AMEN1NPSR1KDM4E | |
| SCHEMBL16140840 | 0.90 | BTN3A1 (0.54) | BTN3A1KMT2AMEN1NPSR1KDM4E | |
| SCHEMBL16140841 | 0.90 | BTN3A1 (0.54) | BTN3A1KMT2AMEN1NPSR1KDM4E | |
| SCHEMBL16024774 | 0.90 | BTN3A1 (0.54) | BTN3A1KMT2AMEN1NPSR1KDM4E | |
| SCHEMBL15588638 | 0.90 | BTN3A1 (0.54) | BTN3A1KMT2AMEN1NPSR1KDM4E | |
| SCHEMBL13470529 | 0.90 | BTN3A1 (0.54) | BTN3A1KMT2AMEN1NPSR1KDM4E | |
| SCHEMBL15721493 | 0.90 | BTN3A1 (0.54) | BTN3A1KMT2AMEN1NPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605144-B2 | Enzyme catalyzed therapeutic compounds | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-20 | — | — | US | disclosed |